Combined PTEN mutation and protein expression associate with overall and disease-free survival of glioblastoma patients

Translational Oncology

Volumn 7, Issue 2, 2014, Pages 196-205.e1

  Xu, Jie ^a   Li, Zhaoli ^b   Wang, Jilin ^a   Chen, Haoyan ^a   Fang, Jing Yuan ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZ 628; BOSUTINIB; BRYOSTATIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLUSTER ANALYSIS; COMET ASSAY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA DAMAGE; GENE MUTATION; GENE SEQUENCE; GENOMIC INSTABILITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; MOUSE; NONHUMAN; NONSENSE MUTATION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SITE DIRECTED MUTAGENESIS; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84902520258     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.02.004     Document Type: Article

References (31)

1. Ahmadloo N, Kani AA, Mohammadianpanah M, Nasrolahi H, Omidvari S, Mosalaei A, and Ansari M (2013). Treatment outcome and prognostic factors of adult glioblastoma multiforme. J Egypt Natl Canc Inst 25, 21-30.
2. Song MS, Salmena L, and Pandolfi PP (2012). The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13, 283-296.
3. Ming M and He YY (2012). PTEN in DNA damage repair. Cancer Lett 319, 125-129.
4. Mayo LD and Donner DB (2002). The PTEN, Mdm2, p53 tumor suppressoroncoprotein network. Trends Biochem Sci 27, 462-467.
5. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, and Cardiff RD, et al (2003). PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent andindependent mechanisms. Cancer Cell 3, 117-130.
6. Rodríguez-Escudero I, Oliver MD, Andrés-Pons A, Molina M, Cid VJ, and Pulido R (2011). A comprehensive functional analysis of PTEN mutations: implications in tumorand autism-related syndromes. Hum Mol Genet 20, 4132-4142.
7. Carico C, Nuño M, Mukherjee D, Elramsisy A, Dantis J, Hu J, Rudnick J, Yu JS, Black KL, and Bannykh SI, et al (2012). Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PloS One 7, e33684.
8. Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, and Schlegel U (2000). Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol 48, 89-94.
9. Ruano Y, Ribalta T, de Lope AR, Campos-Martin Y, Fiaño C, Pérez-Magán E, Hernández-Moneo JL, Mollejo M, and Mélendez B (2009). Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol 131, 257-263.
10. Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, and Goble JM, et al (2008). PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 14, 3993-4001.
11. Minaguchi T, Yoshikawa H, Oda K, Ishino T, Yasugi T, Onda T, Nakagawa S, Matsumoto K, Kawana K, and Taketani Y (2001). PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 7, 2636-2642.
12. Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR, Nicholas MK, Stokoe D, and Haas-Kogan DA (2002). Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8, 1100-1106.
13. Bäcklund LM, Nilsson BR, Goike HM, Schmidt EE, Liu L, Ichimura K, and Collins VP (2003). Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 9, 4151-4158.
14. Endersby R and Baker SJ (2008). PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 27, 5416-5430.
15. Olive PL and Banáth JP (2006). The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1, 23-29.
16. Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
17. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, and Larsson E, et al (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, p 11.
18. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, and Sonkin D, et al (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607.
19. Braun R, Finney R, Yan C, Chen QR, Hu Y, Edmonson M, Meerzaman D, and Buetow K (2013). Discovery analysis of TCGA data reveals association between germline genotype and survival in ovarian cancer patients. PLoS One 8, e55037.
20. Eisen MB, Spellman PT, Brown PO, and Botstein D (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95, 14863-14868.
21. Meyn RE (2009). Linking PTEN with genomic instability and DNA repair. Cell Cycle 8, 2322-2323.
22. Wan X, Yokoyama Y, Shinohara A, Takahashi Y, and Tamaya T (2002). PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway. Cell Death Differ 9, 414-420.
23. Yu T, MacPhail SH, Banáth JP, Klokov D, and Olive PL (2006). Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair 5, 935-946.
24. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, and Siminovitch KA, et al (2003). Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278, 40057-40066.
25. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M, and Wu H (2012). Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72, 1878-1889.
26. Camara-Quintana JQ, Nitta RT, and Li G (2012). Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. Neurosurg Clin N Am 23, 237-246.
27. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, and Strong LC, et al (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872.
28. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, and Jacks T (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860.
29. Hanel W, Marchenko N, Xu S, Yu SX, Weng W, and Moll U (2013). Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 20, 898-909.
30. Freed-Pastor WA and Prives C (2012). Mutant p53: one name, many proteins. Genes Dev 26, 1268-1286.
31. Kim E and Deppert W (2007). Interactions of mutant p53 with DNA: guilt by association. Oncogene 26, 2185-2190.